{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06385080",
            "orgStudyIdInfo": {
                "id": "61186372HNC2002"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-508418-40-00",
                    "type": "REGISTRY",
                    "domain": "EUCT number"
                }
            ],
            "organization": {
                "fullName": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer",
            "officialTitle": "A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
            "acronym": "OrigAMI-4",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-amivantamab-alone-or-in-addition-to-other-treatment-agents-in-participants-with-recurrent-metastatic-head-and-neck-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07-17",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-16",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-23",
            "studyFirstSubmitQcDate": "2024-04-23",
            "studyFirstPostDateStruct": {
                "date": "2024-04-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, and amivantamab in addition to paclitaxel in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel."
        },
        "conditionsModule": {
            "conditions": [
                "Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 117,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Amivantamab Monotherapy (Dose Expansion)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive subcutaneous injection of amivantamab monotherapy 1600 milligrams (mg) (2240 mg, if body weight \\>=80 kilograms \\[kg\\]) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight \\>=80 kg) once every week (q1w) for the remainder of Cycle 1 (Days 8 and 15), and every 3 weeks (q3w) from Cycle 2 onwards.",
                    "interventionNames": [
                        "Biological: Amivantamab"
                    ]
                },
                {
                    "label": "Cohort 2: Amivantamab + Pembrolizumab (Dose Expansion Including Safety Run-in)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight \\>=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight \\>=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards, along with intravenous injection of pembrolizumab 200 mg q3w (on Day 1 of each 21-day cycle).",
                    "interventionNames": [
                        "Biological: Amivantamab",
                        "Biological: Pembrolizumab"
                    ]
                },
                {
                    "label": "Cohort 3A (Dose Confirmation): Amivantamab + Paclitaxel",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight \\>=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight \\>=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards, along with intravenous injection of paclitaxel 175 mg/m\\^2 q3w (on Day 1 of each 21-day cycle) in dose confirmation Cohort 3A. The recommended Phase 2 combination dose (RP2CD) of amivantamab will be determined in conjunction with study evaluation team (SET) in this dose confirmation Cohort 3A.",
                    "interventionNames": [
                        "Biological: Amivantamab",
                        "Drug: Paclitaxel"
                    ]
                },
                {
                    "label": "Cohort 3B (Dose Expansion): Amivantamab + Paclitaxel",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive subcutaneous injection of amivantamab at the determined RP2CD in addition to intravenous injection of paclitaxel 175 mg/m\\^2 q3w (on Day 1 of each 21-day cycle) as confirmed by SET in Cohort 3A.",
                    "interventionNames": [
                        "Biological: Amivantamab",
                        "Drug: Paclitaxel"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Amivantamab",
                    "description": "Amivantamab will be administered subcutaneously.",
                    "armGroupLabels": [
                        "Cohort 1: Amivantamab Monotherapy (Dose Expansion)",
                        "Cohort 2: Amivantamab + Pembrolizumab (Dose Expansion Including Safety Run-in)",
                        "Cohort 3A (Dose Confirmation): Amivantamab + Paclitaxel",
                        "Cohort 3B (Dose Expansion): Amivantamab + Paclitaxel"
                    ],
                    "otherNames": [
                        "JNJ-61186372"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab will be administered intravenously.",
                    "armGroupLabels": [
                        "Cohort 2: Amivantamab + Pembrolizumab (Dose Expansion Including Safety Run-in)"
                    ],
                    "otherNames": [
                        "KEYTRUDA"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Paclitaxel",
                    "description": "Paclitaxel will be administered intravenously.",
                    "armGroupLabels": [
                        "Cohort 3A (Dose Confirmation): Amivantamab + Paclitaxel",
                        "Cohort 3B (Dose Expansion): Amivantamab + Paclitaxel"
                    ],
                    "otherNames": [
                        "TAXOL"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Cohorts 1, 2, and 3B: Objective Response Rate",
                    "description": "ORR is defined as the proportion of participants who achieve either a partial response (PR) or complete response (CR), as defined by investigator assessment using Response Criteria in Solid Tumors (RECIST) version 1.1.",
                    "timeFrame": "2 years and 2 months"
                },
                {
                    "measure": "Cohort 3A: Number of Participants With Dose-limiting Toxicities (DLT)",
                    "description": "Number of participants with DLTs will be reported. A DLT is defined as any of the following: treatment delay of greater than (\\>) 28 days due to unresolved toxicity, non-hematologic toxicity of Grade 3 or higher, hematologic toxicity of Grade 4 neutropenia persisting for \\>7 days or Grade 3 or higher thrombocytopenia with clinically significant bleeding or neutropenic fever of any grade, and liver enzyme elevation.",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Cohort 3A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity",
                    "description": "An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.",
                    "timeFrame": "2 years and 1 month"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cohorts 1, 2, and 3B: Duration of Response (DoR)",
                    "description": "DoR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR.",
                    "timeFrame": "2 years and 2 months"
                },
                {
                    "measure": "Cohorts 1, 2, and 3B: Clinical Benefit Rate (CBR)",
                    "description": "CBR is defined as the percentage of participants achieving a confirmed complete or partial response, or durable stable disease (duration of at least 6 weeks) as defined by RECIST version 1.1.",
                    "timeFrame": "2 years and 2 months"
                },
                {
                    "measure": "Cohorts 1, 2, and 3B: Progression-free Survival (PFS)",
                    "description": "PFS is defined as the time from the first administration of study treatment until the date of objective disease progression or death, whichever comes first, based on investigator assessment using RECIST version 1.1.",
                    "timeFrame": "2 years and 2 months"
                },
                {
                    "measure": "Cohorts 1, 2, and 3B: Overall Survival (OS)",
                    "description": "OS is defined as the time from the first administration of study treatment until the date of death due to any cause.",
                    "timeFrame": "2 years and 2 months"
                },
                {
                    "measure": "Cohorts 1, 2, and 3B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity",
                    "description": "An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events.",
                    "timeFrame": "2 years and 1 month"
                },
                {
                    "measure": "Cohort 1: Maximum Observed Serum Concentration (Cmax) of Amivantamab",
                    "description": "Cmax is defined as maximum observed serum concentration of amivantamab.",
                    "timeFrame": "Predose up to 168 hours post dose on Day 1"
                },
                {
                    "measure": "Cohort 1: Time to Maximum Observed Serum Concentration (Tmax) of Amivantamab",
                    "description": "Tmax is defined as time to maximum observed serum concentration of amivantamab.",
                    "timeFrame": "Predose up to 168 hours post dose on Day 1"
                },
                {
                    "measure": "Cohort 1: Area Under the Serum Concentration Curve Verses Time Curve From Time t1 to t2 (AUC[t1-t2]) of Amivantamab",
                    "description": "AUC(t1-t2) is defined as area under the serum concentration versus time curve from time t1 to time t2 of amivantamab.",
                    "timeFrame": "Predose up to 168 hours post dose on Day 1"
                },
                {
                    "measure": "Cohort 1: Area Under the Curve From Time Zero to tau (AUC[0-tau]) of Amivantamab",
                    "description": "AUC(0-tau) is defined as area under the curve from time 0 to tau hours of amivantamab.",
                    "timeFrame": "Predose up to 168 hours post dose on Day 1"
                },
                {
                    "measure": "Cohort 1: Trough Serum Concentration (Ctrough) of Amivantamab",
                    "description": "Ctrough is defined as the serum concentration of amivantamab.",
                    "timeFrame": "Predose up to 168 hours post dose on Day 1"
                },
                {
                    "measure": "Cohort 1: Accumulation Ratio (R) of Amivantamab",
                    "description": "Accumulation ratio (R) is calculated as area under the serum concentration-time curve from time zero to 168 hours (AUC\\[0-168\\]) value at Cycle 2 Day 1 dose divided by AUC(0-168) value after Cycle 1 Day 1 amivantamab dose.",
                    "timeFrame": "Predose up to 168 hours post dose on Day 1"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have histologically or cytologically confirmed recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that is considered incurable by local therapies. Acceptable prior lines of therapy will be determined according to specific cohort: (a) The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, or larynx; (b) Any known p16 status of tumor must be negative (Note: All participants with an oropharyngeal tumor must have results of p16 status, per local testing); (c) Participants must provide local testing results of programmed cell death ligand 1 (PD-L1) status, if available\n* Participants in Cohorts 1, 2, and 3B must have measurable disease according to RECIST version 1.1. Participants in Cohort 3A must have evaluable disease (defined as having at least 1 non-target lesion according to RECIST version 1.1\n* Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less prior to the first dose of study treatment (except for alopecia or post-radiation skin changes \\[any grade\\], Grade less than or equal to \\[\\<=\\]2 peripheral neuropathy and Grade \\<=2 hypothyroidism stable on hormone replacement)\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Participant must have adequate organ and bone marrow function as follows, without history of red blood cell transfusion, platelet transfusion, or use of granulocyte colony-stimulating factor within 7 days prior to the date of the laboratory test.\n\nParticipants should have: a) Hemoglobin \\>=9 grams per deciliter (g/dL); b) Neutrophils \\>=1.5 x 10\\^3/mcg; c) Platelets \\>=100 x 10\\^3/mcg\n\nExclusion Criteria:\n\n* Uncontrolled illness including any medical history or current (non-infectious) interstitial lung disease (ILD)/ pneumonitis/ pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening\n* Participant with untreated brain metastases leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation\n* Participant with a history of clinically significant cardiovascular disease\n* Received prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study treatment. The maximum required washout is 28 days\n* Received radiotherapy for palliative purposes within 7 days of the first administration of study treatment",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Contact",
                    "role": "CONTACT",
                    "phone": "844-434-4210",
                    "email": "Participate-In-This-Study@its.jnj.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Janssen Research & Development, LLC Clinical Trial",
                    "affiliation": "Janssen Research & Development, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Yale Cancer Center",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06520",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "The University of Chicago Medical Center (UCMC)",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201-2013",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Washington University School Of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "University of Utah Huntsman Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital Yonsei University Health System",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Pantai Hospital Kuala Lumpur",
                    "status": "RECRUITING",
                    "city": "Kuala Lumpur",
                    "zip": "59100",
                    "country": "Malaysia",
                    "geoPoint": {
                        "lat": 3.1412,
                        "lon": 101.68653
                    }
                },
                {
                    "facility": "University Malaya Medical Centre",
                    "status": "RECRUITING",
                    "city": "Kuala Lumpur",
                    "zip": "59100",
                    "country": "Malaysia",
                    "geoPoint": {
                        "lat": 3.1412,
                        "lon": 101.68653
                    }
                },
                {
                    "facility": "Changhua Christian Hospital",
                    "status": "RECRUITING",
                    "city": "ChangHua",
                    "zip": "500",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 24.07327,
                        "lon": 120.56276
                    }
                },
                {
                    "facility": "Chang Kung Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Kaohsiung City",
                    "zip": "833",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 22.61626,
                        "lon": 120.31333
                    }
                },
                {
                    "facility": "National Taiwan University Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "100",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Taipei Veterans General Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "112",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Linkou Chang Gung Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Taoyuan",
                    "zip": "33382",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 24.95233,
                        "lon": 121.20193
                    }
                },
                {
                    "facility": "Addenbrooke's Hospital",
                    "status": "RECRUITING",
                    "city": "Cambridge",
                    "zip": "CB2 0QQ",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 52.2,
                        "lon": 0.11667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",
            "url": "https://www.janssen.com/clinical-trials/transparency"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000077195",
                    "term": "Squamous Cell Carcinoma of Head and Neck"
                },
                {
                    "id": "D000012008",
                    "term": "Recurrence"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000018307",
                    "term": "Neoplasms, Squamous Cell"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "asFound": "Recurrent",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "asFound": "Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "asFound": "Head and Neck Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M20451",
                    "name": "Neoplasms, Squamous Cell",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "C000718215",
                    "term": "Amivantamab-vmjw"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M352636",
                    "name": "Amivantamab-vmjw",
                    "asFound": "Detoxification",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}